Get the Stockscreener App
14.47
1.16%
-0.17
Elanco Animal Health Inc stock is traded at $14.47, with a volume of 3.19M.
It is down -1.16% in the last 24 hours and up +4.10% over the past month.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
See More
Previous Close:
$14.64
Open:
$14.6
24h Volume:
3.19M
Relative Volume:
0.55
Market Cap:
$7.10B
Revenue:
$4.45B
Net Income/Loss:
$205.00M
P/E Ratio:
36.17
EPS:
0.4
Net Cash Flow:
$372.00M
1W Performance:
+1.33%
1M Performance:
+4.10%
6M Performance:
+22.63%
1Y Performance:
+1.76%
1-Day Range:
$14.47
$14.74
1-Week Range:
$14.13
$14.81
52-Week Range:
$8.02
$15.78
Elanco Animal Health Inc Stock (ELAN) Company Profile
Name
Elanco Animal Health Inc
Sector
Phone
877-352-6261
Address
2500 INNOVATION WAY, GREENFIELD
Compare ELAN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELAN
Elanco Animal Health Inc
|
14.47 | 7.10B | 4.45B | 205.00M | 372.00M | 0.40 |
|
RGC
Regencell Bioscience Holdings Ltd
|
18.43 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
157.05 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.15 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.07 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.85 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-24 | Initiated | UBS | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Market Perform |
| Sep-19-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-05-24 | Upgrade | Stifel | Hold → Buy |
| Dec-19-23 | Initiated | Jefferies | Buy |
| Dec-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Apr-20-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-18-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-16-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Sell |
| Jul-12-22 | Initiated | Piper Sandler | Neutral |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Oct-28-21 | Downgrade | Stifel | Buy → Hold |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jun-15-21 | Upgrade | Cleveland Research | Underperform → Neutral |
| May-11-21 | Upgrade | Barclays | Underweight → Equal Weight |
| May-11-21 | Upgrade | Gabelli & Co | Hold → Buy |
| Apr-15-21 | Initiated | Stifel | Buy |
| Mar-22-21 | Downgrade | Gabelli & Co | Buy → Hold |
| Feb-26-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-09-20 | Downgrade | Argus | Buy → Hold |
| Nov-09-20 | Downgrade | Barclays | Overweight → Underweight |
| Aug-20-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-13-20 | Resumed | Credit Suisse | Neutral |
| Aug-04-20 | Resumed | Goldman | Buy |
| Jul-27-20 | Downgrade | Cleveland Research | Neutral → Underperform |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-20 | Initiated | Raymond James | Mkt Perform |
| Dec-19-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Nov-07-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-19 | Initiated | Barclays | Overweight |
| Aug-26-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-15-19 | Upgrade | UBS | Sell → Neutral |
| May-23-19 | Initiated | Guggenheim | Neutral |
| Mar-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-13-19 | Resumed | Morgan Stanley | Equal-Weight |
| Feb-12-19 | Initiated | William Blair | Mkt Perform |
| Jan-23-19 | Initiated | UBS | Sell |
| Jan-15-19 | Initiated | Argus | Buy |
| Oct-15-18 | Initiated | Morgan Stanley | Equal-Weight |
View All
Elanco Animal Health Inc Stock (ELAN) Latest News
Zoetis Stock Is Falling. Why the Animal-Health Company Was Downgraded. - Barron's
Elanco (ELAN) Gains Attention Amid Competitive Market Shifts | E - GuruFocus
United States Veterinary Pain Management Market Size, Share & - openPR.com
Harbor Capital Advisors Inc. Has $9.41 Million Stock Position in Elanco Animal Health Incorporated (NYSE:ELAN) - MarketBeat
Elanco Receives Positive Opinion on Zenrelia (ilunocitinib) from - GuruFocus
Elanco (ELAN) Awaits European Approval for Zenrelia in Dogs - GuruFocus
Elanco gains positive EMA opinion for Zenrelia for itching in dogs - Seeking Alpha
Elanco (ELAN) Awaits EU Approval for Veterinary Drug Zenrelia | ELAN Stock News - GuruFocus
Elanco’s dog allergy treatment Zenrelia gets positive EU opinion By Investing.com - Investing.com Canada
Elanco Gets 'Positive Opinion' on Canine Itch Drug From European Medicines Agency - marketscreener.com
Elanco Receives Positive Opinion on Zenrelia (ilunocitinib) from EU's Committee for Veterinary Medicinal Products (CVMP) | ELAN Stock News - GuruFocus
Elanco Receives Positive Opinion On Zenrelia From EU's Committee - MarketScreener
Elanco Receives Positive Opinion on Zenrelia (ilunocitinib) from EU's Committee for Veterinary Medicinal Products (CVMP) – Company AnnouncementFT.com - Financial Times
BiomEdit CEO: Next gen designer probiotics will disrupt the animal and human health market - AgFunderNews
Elanco Animal Health Incorporated (NYSE:ELAN) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
ELAN Q1 Earnings Call: Innovation and Product Launches Drive Outlook Amid Macro Uncertainty - Yahoo Finance
Elanco Animal Health Clears Technical Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily
Dog Owner Defends Tick Meds Suit Against Elanco, Retailers - Law360
What Makes Elanco Animal Health (ELAN) a New Buy Stock - Yahoo Finance
Is Encompass Health (EHC) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Is the Options Market Predicting a Spike in Elanco Animal Health Stock? - Yahoo Finance
Veterinary Vaccines Market Set to Surge as Global Demand - openPR.com
Elanco Animal Health Incorporated (NYSE:ELAN) Given Average Rating of “Hold” by Analysts - Defense World
Report reveals widespread impact of chronic itch in dogs - Veterinary Practice News
Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief - ACCESS Newswire
Elanco Animal Health Appoints Robert VanHimbergen as Chief Financial Officer - Pet Age
Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief | ELAN Stock News - GuruFocus
Sanders Morris Harris LLC Purchases 81,750 Shares of Elanco Animal Health Incorporated (NYSE:ELAN) - MarketBeat
Equine Healthcare Market Analysis: Trends, Key Players, - openPR.com
Animal Depression Medication Market Detailed in New Research Report | Zoetis Inc., Elanco Animal Health - openPR.com
Ameriprise Financial Inc. Has $1.18 Million Stake in Elanco Animal Health Incorporated (NYSE:ELAN) - Defense World
Companion Animal Health Market -Depth Analysis, Future Trends - openPR.com
Veterinary Vaccines Market Size, Share & Forecast 2025-2033 | - openPR.com
Cetera Investment Advisers Purchases 4,553 Shares of Elanco Animal Health Incorporated (NYSE:ELAN) - Defense World
Elanco at Stifel Jaws & Paws: Strategic Growth and Innovation By Investing.com - Investing.com Canada
Elanco appoints Robert VanHimbergen as chief financial officer - Feed Strategy
Elanco appoints VanHimbergen as CFO - Feedstuffs
Transcript : Elanco Animal Health Incorporated Presents at Stifel Jaws & Paws Conference 2025, May-29-2025 08 - marketscreener.com
Elanco names Robert VanHimbergen as new CFO By Investing.com - Investing.com South Africa
Elanco Appoints Robert (Bob) VanHimbergen as Chief Financial Officer - citybiz
How Elanco Plans on Winning in the Pet Wellness Boom - marketscreener.com
Elanco Animal Health Incorporated Announces Change of Executive Vice President - marketscreener.com
Elanco Animal Health Incorporated Reconfirms Earnings Guidance for the Second Quarter and Full Year 2025 - marketscreener.com
Elanco Animal Health Appoints Robert VanHimbergen As CFO, Reaffirms Q2, FY25 Guidance - Nasdaq
Elanco (ELAN) Names Robert VanHimbergen as New CFO | ELAN Stock News - GuruFocus
Elanco Animal Health (ELAN) Maintains Revenue and Earnings Outlook for Q2 | ELAN Stock News - GuruFocus
Elanco Animal Health (ELAN) Reaffirms FY25 Revenue and EBITDA Ou - GuruFocus
Elanco Appoints New CFO to Drive Growth - TipRanks
Elanco names Robert VanHimbergen as new CFO - Investing.com
Elanco Appoints Robert (Bob) VanHimbergen as Chief Financial Officer | ELAN Stock News - GuruFocus
Elanco Animal Health (ELAN) Reaffirms FY25 Revenue and EBITDA Outlook | ELAN Stock News - GuruFocus
Elanco Animal Health Inc Stock (ELAN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Elanco Animal Health Inc Stock (ELAN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kurzius Lawrence Erik | Director |
Mar 11 '25 |
Buy |
10.20 |
10,000 |
102,000 |
111,459 |
| HOOVER R DAVID | Director |
Mar 05 '25 |
Buy |
10.90 |
25,000 |
272,558 |
210,000 |
| Harrington Michael J | Director |
Aug 22 '24 |
Buy |
14.85 |
3,500 |
51,974 |
81,094 |
| Simmons Jeffrey N | PRESIDENT, CEO AND DIRECTOR |
Aug 12 '24 |
Buy |
13.01 |
100,000 |
1,300,610 |
145,000 |
1.29%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):